Author:
Lester J E,Dodwell D,Horsman J M,Mori S,Coleman R E
Publisher
Springer Science and Business Media LLC
Reference18 articles.
1. Coleman RE (2004) Hormone and chemotherapy induced bone loss in breast cancer. Oncology 18: 16–20
2. Coombes C, Hall E, Gibson L, Paridaens R, Jassem J, Delozier T, Jones S, Alvares I (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350: 1081–1092
3. Gnant M, Jakesz R, Mlineritsch B (2004) Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole vs goserelin plus tamoxifen-bone density sub-protocol results of a randomised multicentre trial (ABCSG-12). Breast Cancer Res Treat 88: S8 Abstract 6
4. Goss P, Ingle J, Martino S, Robert N, Muss H, Piccart M, Castiglione M, Tu D, Shepherd L, Pritchard K (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349: 1793–1802
5. Hillner B, Ingle J, Chlebowski R, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S (2003) American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21: 4042–4057
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献